JP2023545372A - デクスメデトミジン塩酸塩を用いた双極性障害及び精神病の治療 - Google Patents

デクスメデトミジン塩酸塩を用いた双極性障害及び精神病の治療 Download PDF

Info

Publication number
JP2023545372A
JP2023545372A JP2023518752A JP2023518752A JP2023545372A JP 2023545372 A JP2023545372 A JP 2023545372A JP 2023518752 A JP2023518752 A JP 2023518752A JP 2023518752 A JP2023518752 A JP 2023518752A JP 2023545372 A JP2023545372 A JP 2023545372A
Authority
JP
Japan
Prior art keywords
dexmedetomidine
pharmaceutically acceptable
subject
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023518752A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022076818A5 (https=
JP2023545372A5 (https=
Inventor
ヨッカ，フランク
リシンガー，ロバート
ビボ，マイケル デ
ポストマ，フリソ
Original Assignee
バイオエクセル セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオエクセル セラピューティクス，インコーポレイテッド filed Critical バイオエクセル セラピューティクス，インコーポレイテッド
Publication of JP2023545372A publication Critical patent/JP2023545372A/ja
Publication of JPWO2022076818A5 publication Critical patent/JPWO2022076818A5/ja
Publication of JP2023545372A5 publication Critical patent/JP2023545372A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2023518752A 2020-10-08 2021-10-08 デクスメデトミジン塩酸塩を用いた双極性障害及び精神病の治療 Pending JP2023545372A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063089135P 2020-10-08 2020-10-08
US63/089,135 2020-10-08
PCT/US2021/054171 WO2022076818A1 (en) 2020-10-08 2021-10-08 Treatment of bipolar disorders and psychosis using dexmedetomidine hydrochloride

Publications (3)

Publication Number Publication Date
JP2023545372A true JP2023545372A (ja) 2023-10-30
JPWO2022076818A5 JPWO2022076818A5 (https=) 2024-10-15
JP2023545372A5 JP2023545372A5 (https=) 2024-10-15

Family

ID=81126063

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023518752A Pending JP2023545372A (ja) 2020-10-08 2021-10-08 デクスメデトミジン塩酸塩を用いた双極性障害及び精神病の治療

Country Status (11)

Country Link
US (1) US20240024289A1 (https=)
EP (1) EP4225305A4 (https=)
JP (1) JP2023545372A (https=)
KR (1) KR20230084186A (https=)
CN (1) CN116615243A (https=)
AU (1) AU2021356687A1 (https=)
CA (1) CA3195133A1 (https=)
IL (1) IL301971A (https=)
MX (1) MX2023003993A (https=)
TW (1) TW202228682A (https=)
WO (1) WO2022076818A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102793584B1 (ko) 2016-12-31 2025-04-09 바이오엑셀 테라퓨틱스 인코포레이티드 불안의 치료를 위한 설하 덱스메데토미딘의 용도
PL3813802T3 (pl) 2018-06-27 2025-04-22 Bioxcel Therapeutics, Inc. Formulacje błony zawierające deksmedetomidynę i sposoby ich wytwarzania
EP3999058A4 (en) 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. NON-SEDATIVE DEXMEDETOMIDINE-BASED TREATMENT REGIMEN
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020503323A (ja) * 2016-12-31 2020-01-30 バイオエクセル セラピューティクス，インコーポレイテッド 激越の治療のための舌下デクスメデトミジンの使用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8242158B1 (en) * 2012-01-04 2012-08-14 Hospira, Inc. Dexmedetomidine premix formulation
DK2906213T3 (en) * 2012-10-15 2018-02-19 Orion Corp VETERINARY PROCEDURE FOR RELIEFING NOISE SENSITIVITY
CA2924190C (en) * 2013-10-07 2019-07-09 Teikoku Pharma Usa, Inc. Methods and compositions for treating withdrawal syndromes using non-sedative dexmedetomidine transdermal compositions
EP3999058A4 (en) * 2019-07-19 2023-05-03 Bioxcel Therapeutics, Inc. NON-SEDATIVE DEXMEDETOMIDINE-BASED TREATMENT REGIMEN

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020503323A (ja) * 2016-12-31 2020-01-30 バイオエクセル セラピューティクス，インコーポレイテッド 激越の治療のための舌下デクスメデトミジンの使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BMJ CASE REPORTS, JPN6025041232, 2011, pages 1 - 2, ISSN: 0005701278 *
CLINICALTRIALS.GOV: NCT04276883, JPN6025041230, ISSN: 0005701279 *

Also Published As

Publication number Publication date
EP4225305A4 (en) 2024-10-23
AU2021356687A1 (en) 2023-06-15
CA3195133A1 (en) 2022-04-14
WO2022076818A1 (en) 2022-04-14
MX2023003993A (es) 2023-05-24
KR20230084186A (ko) 2023-06-12
EP4225305A1 (en) 2023-08-16
CN116615243A (zh) 2023-08-18
AU2021356687A9 (en) 2024-10-03
IL301971A (en) 2023-06-01
TW202228682A (zh) 2022-08-01
US20240024289A1 (en) 2024-01-25

Similar Documents

Publication Publication Date Title
US12109196B2 (en) Non-sedating dexmedetomidine treatment regimens
RU2572692C2 (ru) Сублингвальные композиции дексмедетомидина и способы их применения
JP2022058678A (ja) ブプレノルフィンの乱用抵抗性粘膜付着性送達デバイス
JP2023545372A (ja) デクスメデトミジン塩酸塩を用いた双極性障害及び精神病の治療
US20250228833A1 (en) Methods and compositions for treating agitation
BR112020026672A2 (pt) Formulações de filme contendo dexmedetomidina e métodos para produzi-las
RS54764B1 (sr) Sredstvo za transmukozalnu isporuku sa povećanim nakupljanjem
TW202317101A (zh) 治療抑鬱狀態之方法
US12090140B2 (en) Non-sedating dexmedetomidine treatment regimens
JP2023506537A (ja) アゴメラチンを含有する経粘膜治療システム
CN117750956A (zh) 用于治疗抑郁状态的方法
WO2024263973A1 (en) Dexmedetomidine treatment regimens
EA045213B1 (ru) Пленочный состав, содержащий дексмедетомидин, и способ его получения
EA040771B1 (ru) Пленочные составы, содержащие дексмедетомидин, и способы их получения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241004

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250930

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251006

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260331